Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Meta Expands AI Training With Employee Activity Tracking Tools 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
DALLAS, May 18, 2017 -- TissueGen® Inc., developer of ELUTE® fiber, a groundbreaking biodegradable fiber format for advanced drug delivery, nerve regeneration, and tissue engineering, was awarded the title of Most Innovative Small Size Company by the World Textile Information Network (WTiN), publisher of international technical textiles magazine Future Textiles (formerly known as Future Materials).
TissueGen Founder and CSO, Dr. Kevin Nelson, and President and CEO, Christopher Knowles, accepted the award at the Future Textiles Award Gala in Frankfurt, Germany this past week. Organized by WTiN, the third edition of the biennial awards celebrated the best innovations in the technical textiles industry.
TissueGen’s patented process for manufacturing commercially available ELUTE® fiber occurs at or below body temperature thereby preserving the biologic activity of incorporated biologics and pharmaceutical compounds. ELUTE fiber technology enables controlled sustained delivery of a broad range of sensitive biologics and pharmaceuticals directly at the topical application or implant site and may potentially orchestrate and improve the healing process. ELUTE fiber enables tissue engineering and regenerative medicine applications never before possible.
“We are honored to receive this recognition from WTiN as further testament to the groundbreaking work conducted by our scientists at TissueGen,” said Knowles. “We were privileged to participate in this special event and congratulate all the winners and finalists.”
A full list of winners is available here.
About TissueGen
TissueGen® Inc. is the developer of ELUTE® fiber, a groundbreaking biodegradable fiber format for advanced drug delivery, nerve regeneration, and tissue engineering. TissueGen manufactures biodegradable polymer-based fibers with the broadest drug delivery capabilities available today. ELUTE fiber can directly replace standard fibers used in medical devices currently on the market and may provide significantly improved clinical outcomes by delivering sensitive therapeutic agents directly at the implant or topical application site in controlled, sustained release profiles. ELUTE fiber may enable medical device developers to guide the body’s healing and regenerative processes.
For more information, please visit www.tissuegen.com.
For more information contact: Jordan Bouclin SVM Public Relations 401-490-9700 [email protected]
